

RECEIVED  
CENTRAL FAX CENTER  
NOV 01 2006

## CLAIM AMENDMENTS

1. previously cancelled
2. previously cancelled
3. previously cancelled
4. previously cancelled
5. previously cancelled
6. (previously presented) A method of treating a human immunodeficiency virus (HIV) infection comprising:  
reducing HIV virus load or reducing HIV particle formation in an individual by  
administering an effective amount of a pharmaceutical composition comprising  
Xestospongins C (XeC) to said individual in need of said treatment.
7. previously cancelled
8. previously cancelled
9. previously cancelled
10. previously cancelled
11. previously cancelled
12. previously cancelled
13. previously cancelled
14. previously cancelled
15. previously cancelled
16. previously cancelled
17. previously cancelled
18. previously cancelled
19. previously cancelled
20. previously cancelled
21. previously cancelled

22. previously cancelled
23. previously cancelled
24. previously cancelled
25. previously cancelled
26. previously cancelled
27. previously cancelled
28. previously cancelled
29. previously cancelled
30. previously cancelled
31. previously cancelled
32. (previously presented) The method according to claim 6 wherein the XeC is administered at a concentration between 0.1  $\mu$ M to 100  $\mu$ M.
33. (previously presented) The method according to claim 6 wherein the XeC is administered at a dosage between 0.1  $\mu$ g to 10 mg.
34. (previously presented) The method according to claim 6 wherein the XeC is administered in combination with an effective amount of at least one of the following selected from the group consisting of azidothymidine, lamivudine, dideoxyinosidine, ritonavir, an HIV protease inhibitor and an HIV reverse transcriptase inhibitor.
35. (previously presented) The method according to claim 32 wherein the XeC is administered at a concentration between 0.1  $\mu$ M to 10  $\mu$ M.
36. (previously presented) The method according to claim 35 wherein the XeC is administered at a concentration between 1  $\mu$ M to 10  $\mu$ M.
37. (previously presented) The method according to claim 32 wherein the XeC is administered at a concentration between 1  $\mu$ M to 100  $\mu$ M.